These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23052172)

  • 1. The economic crisis and cancer chemotherapy: the role of the oncologist.
    Rescigno P; Imbevaro S; Jirillo A
    Tumori; 2012; 98(4):532-3. PubMed ID: 23052172
    [No Abstract]   [Full Text] [Related]  

  • 2. Tackling Cost: A Prescription for Spending Wisely.
    Tempero M
    J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
    [No Abstract]   [Full Text] [Related]  

  • 3. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 4. [The costs of oncology. Results of an innovative research].
    Piccinini M; Nicolis F; Venturini M
    Tumori; 2008; 94(3):1-4. PubMed ID: 18705421
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 6. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic evaluation of trends in cancer therapy. Marginal or average costs?
    Goddard M; Hutton J
    Int J Technol Assess Health Care; 1991; 7(4):594-603. PubMed ID: 1778704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. United healthcare, five oncology practices try bundled payments.
    Goozner M
    J Natl Cancer Inst; 2011 Jan; 103(1):8-10. PubMed ID: 21169535
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies.
    Cheung MC; Sabharwal M; Chambers A; Han D; Sabarre KA; Chan K
    J Clin Oncol; 2016 Apr; 34(12):1428-9. PubMed ID: 26884567
    [No Abstract]   [Full Text] [Related]  

  • 10. Communicating with patients about chemotherapy costs.
    de Lemos ML
    J Clin Oncol; 2007 May; 25(15):2142; author reply 2142. PubMed ID: 17513825
    [No Abstract]   [Full Text] [Related]  

  • 11. Early Returns From the Era of Precision Medicine.
    Cutler DM
    JAMA; 2020 Jan; 323(2):109-110. PubMed ID: 31935015
    [No Abstract]   [Full Text] [Related]  

  • 12. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 13. Introduction and commentary: Paving the way for biosimilars in oncology.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S1-4. PubMed ID: 24267943
    [No Abstract]   [Full Text] [Related]  

  • 14. Using cancer registries to supplement clinical trial data and inform regulatory decision.
    da Costa FA; da Costa Miranda A
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1319-1321. PubMed ID: 31788909
    [No Abstract]   [Full Text] [Related]  

  • 15. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 16. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 18. Minimalism in oncology.
    The Lancet Oncology
    Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372
    [No Abstract]   [Full Text] [Related]  

  • 19. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
    Raymakers AJN; Regier DA; Peacock SJ
    Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should the American Society of Clinical Oncology Ask for Peer Review Before Publishing Its Advocacy Research?
    Bach PB
    J Clin Oncol; 2016 Dec; 34(36):4447-4448. PubMed ID: 27998217
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.